Innovacell raised a total of 1.06 billion yen through FUNDINNO PLUS+

Innovacell K.K. (Head Office: Shinagawa-ku, Tokyo; Representatives: Colin Lee Novick, CEO, and Jason David Sieger, COO), a company dedicated to improving health and quality of life through cell therapy for the treatment of fecal and urinary incontinence, is pleased to announce that it raised funds on December 27 through the “FUNDINNO PLUS+” service, which enables direct investment from specific investors*.

FUNDINNO PLUS+: https://fundinno.com/plus/specific_investor

* Specific investors are considered “professional investors” with sufficient knowledge, experience, assets, and risk management capabilities regarding financial products. Therefore, when financial instruments business operators develop or solicit financial products for these investors, certain legal regulations may be exempted.

Our group is currently conducting a Phase III Japan-Europe international joint clinical trial for the regenerative medical product “ICEF15,” targeting the treatment of urgent fecal incontinence. Simultaneously, we are building a framework for the launch and sales of ICEF15 in Japan, the U.S., and Europe. We are also in the process of Series D fundraising with a view toward going public, aiming to close by March 2025, and are actively negotiating with domestic and international investors.

Receiving support from specific investors through FUNDINNO PLUS+ offers a new funding option for startups developing regenerative medical products in Japan. It also empowers startup executives to focus more on executing their strategies.

Our group plans to use the funds to advance the Phase III Japan-Europe international trial of ICEF15, prepare for the Phase III trial in the U.S., build a manufacturing system for ICEF15 in Japan, conduct R&D for pipeline products beyond ICEF15, and accelerate preparations for going public.

“We are honored that FUNDINNO, a company that supports challengers innovators under the mission “Creating a future where everyone can compete fairly to build a future,” has chosen Innovacell as an investment destination. Understanding the nature of biotech, which requires significant upfront investment, FUNDINNO enabled us to raise a large-scale investment of 1.06 billion yen from specific investors. This would not have been possible without FUNDINNO. This investment through FUNDINNO PLUS+ is not only a great encouragement for our company but also for the biotech industry in Japan. Innovacell remains committed to delivering treatments for fecal incontinence to patients as quickly as possible.

Our mission is to make Japan’s venture market more open and democratic, eliminating disparities in information and opportunities for all entrepreneurs and investors. We provide diverse options for entrepreneurs and deliver investor support to them. We continue to drive transformation toward a future open to those with aspirations.

Japan’s first equity-based crowdfunding service, matching companies seeking funding with fan investors who want to support their business.

A service that matches companies seeking large-scale funding with investors interested in angel investing in startups.

Japan’s first secondary market for trading unlisted shares online.

A management platform for venture companies, supervised by lawyers, supporting CXOs with shareholder management, general meetings, financial management, IR distribution, and more.

Location: 5-29-11 Shiba, Minato-ku, Tokyo
CEOs: Yuki Shibahara / Manabu Oura
Capital and reserves: ¥9.8703 billion (as of October 31, 2024)
Established: November 26, 2015
Registered Financial Instruments Business Operator: Kanto Finance Bureau Director (Kinsho) No. 2957
Member: Japan Securities Dealers Association
Website: https://corp.fundinno.com

Please refer to the “Important Information Disclosure” on our website (https://fundinno.com/disclosure) and the pre-contract documents for each project. Investment decisions should be made at your own discretion.

Note: This press release is intended to publicly share information about FUNDINNO’s services and achievements and is not created for the purpose of soliciting investments.